NeuroCentrix

NeuroCentrix provides care across three states focusing on treatment-resistant depression, brain injury and early dementia. We have access to depression and early dementia research trials funding through NHMRC and pharmaceutical company funded research. For treatment-resistant depression we offer TMS and esketamine in three sites: Noble Park, Ballarat and Toowong. David’s subspecialty is in old-age psychiatry, neuropsychiatry (acquired brain injury) and treatment-resistant mood disorders.